EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids

Suzanne Nielsen iD, João Pedro Silva, Jermaine D Jones iD, Alex Krotulski iD, Dilkushi Poovendran, Deusdedit Muzangizi, Gilles Forte, Jason White, Sandra D Comer

Drug and Alcohol Review · 2026-01 · 45 (1)

DOI: 10.1111/dar.70040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug and Alcohol Review, online erschienen am 15.10.2025. Verfasst von Suzanne Nielsen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Naloxone, Narcotic Antagonists, Analgesics, Opioid, Opioid-Related Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, WHO, World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new synthetic opioids, with a focus on synthetic opioids evaluated for international control since 2020. It highlights key findings that can inform our understanding of these substances and inform harm reduction strategies.

Methods

A narrative review was conducted using critical reviews from the World Health Organization Expert Committee on Drug Dependence and supplementary literature. Data extraction focused on pharmacological profiles, behavioural effects, potency estimates, and naloxone effectiveness.

Results

Thirteen synthetic opioids were examined, with potencies ranging from similar to morphine to exceeding that of fentanyl. Naloxone demonstrated efficacy in reversing overdose symptoms for most substances, although higher doses or infusions were occasionally required. Discussion and Conclusions The variability in nitazene potency and common unintended use underscores the need for widespread education, broad naloxone access and robust drug‐checking initiatives. Key challenges include the detection of nitazenes in polydrug contexts and their presence in substances sold as other drugs, including falsified pharmaceuticals. Emerging evidence suggests that naloxone can reverse acute poisonings with benzimidazole opioids. However, no studies have examined the effectiveness of medications for treating opioid use disorder (e.g., methadone, buprenorphine, naltrexone) in people who are physically dependent on nitazenes. Future research should address this important knowledge gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaloxoneNarcotic AntagonistsAnalgesics, OpioidOpioid-Related DisordersBenzimidazolesHumansDrug Overdose

Stichwörter der Autor:innen

antinociceptionnaloxonenitazenespotencysynthetic opioids

Substanzen

NaloxoneNarcotic AntagonistsAnalgesics, OpioidBenzimidazoles

Autor:innen und Institutionen

  • Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia.
  • UCIBIO - Applied Molecular Biosciences Unit/i4HB - Associate Laboratory Institute for Health and Bioeconomy, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto,…
  • Division on Substance Use Disorders, Columbia University Irving Medical Center & New York State Psychiatric Institute, New York, USA.
  • Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, USA.
  • Department of Health Product Policies and Standards, World Health Organization, Geneva, Switzerland.
  • Division of Access to Medicines and Health Products, World Health Organization, Geneva, Switzerland.

ORCID-Profile: Suzanne Nielsen, Jermaine D Jones, Alex Krotulski

Förderung

  • Fundação para a Ciência e a Tecnologia
  • WHO
  • World Health Organization
  • National Health and Medical Research Council
  • Intramural NIH HHS

Zitieren

APA

Nielsen, S., Silva, J. P., Jones, J. D., Krotulski, A., Poovendran, D., Muzangizi, D., Forte, G., White, J., & Comer, S. D. (2026). Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids. Drug and Alcohol Review, 45(1). https://doi.org/10.1111/dar.70040

Vancouver

Nielsen S, Silva JP, Jones JD, Krotulski A, Poovendran D, Muzangizi D, et al. Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids. Drug and Alcohol Review. 2026;45(1). doi:10.1111/dar.70040

BibTeX
@article{Nielsen2026,
  author = {Nielsen, Suzanne and Silva, João Pedro and Jones, Jermaine D and Krotulski, Alex and Poovendran, Dilkushi and Muzangizi, Deusdedit and Forte, Gilles and White, Jason and Comer, Sandra D},
  title = {Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids},
  journal = {Drug and Alcohol Review},
  year = {2026},
  volume = {45},
  number = {1},
  doi = {10.1111/dar.70040}
}
Kostenlos starten →